ASH 2019 | CANDOR: KdD is a new regimen for R/R MM
Saad Usmani
• 7 Dec 2019
Saad Usmani, MD, FACP, Levine Cancer Institute, Charlotte, NC, discusses the rationale and results from the primary analysis of CANDOR (NCT03158688), a multicenter, phase III randomized study comparing carfilzomib, dexamethasone and daratumumab (KdD) vs. carfilzomib and dexamethasone (Kd) in relapsed/refractory (R/R) multiple myeloma (MM). This study demonstrated that KdD resulted in a favorable efficacy, was generally well tolerated and represents an efficacious new regimen for R/R MM. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
